Clinical Trial: An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy

U.S., July 16 -- ClinicalTrials.gov registry received information related to the study (NCT07705568) titled 'An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy' on July 10.

Brief Summary: The goals of this interventional study are (1) to evaluate the safety and tolerability of multiple doses of PST-611 in men and women over the age of 65 with geographic atrophy secondary to age-related macular degeneration and (2) to assess efficacy of multiple doses of PST-611 by assessing retinal morphology and visual function changes over time.

Participants will:

* receive one dose every 20 weeks, for a total of 3 doses.

* will be followed up for a total of 52 weeks following the first PST-611 ...